Compare Repligen Corporation Common Stock (RGEN) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Vale SA — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Vale SA trades at $13.05 (market cap $57.30B). The key difference: Vale SA is far larger — about 5.1× Repligen Corporation Common Stock's market cap, and Vale SA pays a 8.9% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Vale SA for 110 Days on average.
| RGEN | VALE | |
|---|---|---|
Market Cap | $11.14B | $57.30B |
Volume | 1,259,263 | 25,010,417 |
Sector | Health | Basic Materials |
52-Week High | $194.57 | $17.82 |
52-Week Low | $102.87 | $11.10 |
Typical Hold Time | 0 Days | 110 Days |
Enterprise Value | $11.02B | $73.54B |
Dividend Yield | — | 8.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
VALE trades at $13.21, down 2.29% today, with a bearish technical signal and three consecutive quarterly EPS misses. The stock shows mixed fundamentals with a P/E of 26.74 and net income margin of 5.11%, while cash flow improved to $2.42B in 2025. Recent news highlights pressure from US steel expansion plans and rising operational costs.
Analyst consensus is cautious with 57% hold ratings and a $15.93 price target, suggesting 21% upside. Key risks include iron ore price volatility, Brazilian regulatory exposure, and margin compression from cost inflation. The base metals segment growth provides some diversification support amid cyclical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
